对血液吸收的成分,代谢学和转录学的综合分析揭示了Tianshu Capsule的有效成分和机制
Jie Dong1, Youwei Gu2, Jing Liu2
1College of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China; State Key Laboratory of Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture (Jiangsu Kanion Pharmaceutical Co., Ltd.), Jiangsu, Nanjing, 211112.China.
概括
泰安舒囊 (TSC) 通过调节关键代谢物和参与血管度的基因,有效治疗老鼠的偏头痛. 这项研究确定了特定的化合物和途径,为偏头痛治疗机制提供了新的见解.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 代谢学 代谢学 代谢学
背景情况:
- 偏头痛是一种流行的神经血管疾病,治疗选择有限.
- 提安舒囊 (TSC),源自 Chuanxiong Rhizoma 和 Gastrodiae Rhizoma,显示可能缓解偏头痛的症状.
- 在偏头痛中TSC的有效性背后的精确机制在很大程度上仍未被探索.
研究的目的:
- 为了阐明Tianshu囊 (TSC) 的活性成分和潜在机制,在一只老鼠模型中分析尼甘 (NTG) 诱导的偏头痛.
- 为了识别通过TSC治疗调节的特定代谢物和基因.
主要方法:
- 建立了一种酸甘油 (NTG) 诱导的老鼠模型来评估TSC的疗效.
- 采用超高性能液态染色学-四极飞行时间质谱法 (UHPLC-Q-TOF/MS) 进行血液成分和代谢物分析.
- 利用转录组学分析差异性基因表达和综合代谢组学和转录组学进行途径分析.
主要成果:
- 在NTG诱导的老鼠模型中,TSC显著缓解了偏头痛症状.
- 确定了37种差异表达代谢物 (DEM) 和58种差异表达基因 (DEG).
- 突出了关键的活性成分,包括 (Z) -ligustilide,烯酸酸盐和senkyunolide N,并确定了 lysophosphatidylethanolamine (LPE) 和 O-phospho-L-serine (L-SOP) 作为关键代谢物,以及 Vanin-1 (Vnn-1) 和 Calsequestrin 2 (Casq2) 作为关键基因.
结论:
- 州囊 (TSC) 在老鼠中显示出显著的偏头痛改善作用.
- 通过调节LPE和L-SOP代谢物以及调节Vnn1和Casq2基因表达来发挥TSC的治疗作用.
- 这些分子变化集体影响血管扩张,为TSC在偏头痛治疗中的有效性提供了机制基础.
相关概念视频
Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Drug Absorption Mechanism: Passive Membrane Transport
Passive transport is a method of drug absorption where small, lipid-soluble drugs can move across the cell membrane. This movement happens along the concentration gradient, which is a natural flow from higher to lower concentration areas. The speed at which the drug moves is directly related to its lipid–water partition coefficient. This means that the more a drug dissolves in lipids, the faster it diffuses or spreads throughout the body. It is important to note that most drugs are either weak...
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
Certain large, lipid-insoluble drug molecules that resemble amino acids, peptides, or glucose, require specialized carrier proteins to facilitate their diffusion across cell membranes. This transport can occur through either facilitated diffusion, which does not require energy input, or active transport, which does require energy input.
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Mechanisms of Drug Absorption: Paracellular, Transcellular, and Vesicular Transport
Drugs need to permeate cell membranes to reach their target sites after administration. Orally administered drugs must transcend intestinal epithelial membrane barriers to infiltrate the systemic circulation. Drugs with a molecular weight of less than 500 Daltons diffuse through gaps between neighboring cells, called paracellular pathways.
However, most drugs use the transcellular route, traversing directly through the cell membranes via two mechanisms: passive and active transport. Passive...
However, most drugs use the transcellular route, traversing directly through the cell membranes via two mechanisms: passive and active transport. Passive...

